Home Bratislava Medical Journal 2020 Bratislava Medical Journal Vol.121, No.12, p.858–863,2020

Journal info


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564


Aims and Scope
Editorial Info
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.121, No.12, p.858–863,2020

Title: Is ceftriaxone effective in experimental brain ischemia/reperfusion injury?
Author: E. Arslan, M. O. Biyik, M. Kosucu, A. R. Guvercin, A. Bodur, A. Alver

Abstract: OBJECTIVE: The aim of the present study was to investigate the neuroprotective effect of ceftriaxone in a rat brain ischemia/reperfusion injury model.
METHODS: The oxidative stress parameter, malondialdehyde (MDA) levels with or without ceftriaxone treatment in brain ischemia/reperfusion injured rats as well as in controls were measured in serum and brain tissue. Motor examinations of the rats were also performed. One-way Analysis of Variance (ANOVA) test was used for analysis. Duncan’s Multiple Range Test was performed in multiple comparisons. p < 0.05 were considered statistically significant.
 RESULTS: The data of this study showed that ceftriaxone treatment reduced the MDA levels in brain tissues in ischemia/reperfusion injured rats. Moreover, Bederson motor scores were higher in the ceftriaxone treated group as compared to the ischemia group (p = 0.092).
CONCLUSION: These results suggest that ceftriaxone could be beneficial for the prevention of brain ischemia/reperfusion injury caused by acute arterial occlusion through reducing the tissue MDA level (Tab. 2, Fig. 5, Ref. 24).

Keywords: ceftriaxone, ischemia/reperfusion injury, antioxidant, neuroprotective, stroke
Published online: 09-Dec-2020
Year: 2020, Volume: 121, Issue: 12 Page From: 858, Page To: 863

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.